Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTR-EU
NCT06362668Completed
- Sponsor
- Reprieve Cardiovascular
- Start
- May 2024
- Primary completion
- Oct 2024
- Countries
- 2
01
Overview
Randomised, open-label trial (2 arms), sponsored by Reprieve Cardiovascular. Primary endpoints: Total sodium loss per 24 hours at 72 hours and Composite of clinically significant acute kidney injury, severe electrolyte abnormality, or symptomatic hypotension/hypertensive emergency at 90 days. Started May 2024; status: completed.
Beyond the preview
Go deeper on NCT06362668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362668.